Home › Disorders of Excessive Somnolence › Michigan › Lansing
Disorders of Excessive Somnolence clinical trials in Lansing, MI
5 studies for Disorders of Excessive Somnolence are looking for participants at sites in and around Lansing (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
RecruitingPhase 3
- Alkermes Investigational Site, Lansing
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
RecruitingPhase 3
- Alkermes Investigational Site, Lansing
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
RecruitingPhase 3
- Alkermes Investigational Site, Lansing
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
RecruitingPhase 2/3
- Alkermes Investigational Site, Lansing
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
RecruitingPhase 3
- Clinical Research Site, Lansing
Disorders of Excessive Somnolence trials in other cities
- San Antonio, TX9 studies
- Atlanta, GA9 studies
- Cincinnati, OH9 studies
- Miami, FL8 studies
- Charlotte, NC8 studies
- Austin, TX7 studies
- Columbia, SC7 studies
- Orlando, FL7 studies
- Sugar Land, TX7 studies
- Brandon, FL6 studies
- Los Angeles, CA5 studies
- Macon, GA5 studies
Other studies in Lansing
- Lung Cancer11 studies
- Breast Cancer10 studies
- Prostate Cancer10 studies
- Non-Small Cell Lung Cancer9 studies
- Cancer (all types)6 studies
- Laryngeal Cancer5 studies
- Bladder Cancer5 studies
- Multiple Myeloma4 studies
- Urothelial (Transitional Cell) Carcinoma4 studies
- Sleep Disorders4 studies
- Colon Cancer4 studies
- Colorectal Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.